Treatment of aggressive XXXX with chemotherapy in combination with filgrastim.

@entity1 @entity632 @entity1261 @entity706 @entity5 @entity229 @entity3726 @entity786 @entity1398 @entity1891 @entity1893
@entity1893 ( @entity1893 ) is one of the ten most common @entity5 in the developed world. The incidence has increased significantly over the past two decades and it is a particular burden in @entity1 over the age of 60 years. The gold standard for primary treatment of aggressive @entity1893 is combination chemotherapy with @entity786 , @entity632 , @entity1891 and @entity229 ( @entity3726 ). Haematological growth factors, such as @entity1261 ( @entity1261 ), can be used to ameliorate chemotherapy-induced @entity1398 , thus facilitating delivery of chemotherapy at the planned dose intensity. The International Prognostic Index is able to identify high-risk @entity1 who are unlikely to be cured with standard primary chemotherapy. In these @entity1 , the use of dose-intensive therapy, including high-dose chemotherapy with stem cell support, is being evaluated as potential primary therapy. Stem cell transplantation is currently the treatment of choice for @entity1 with relapsed @entity1893 or those with chemosensitive refractory disease. Autologous peripheral blood stem cells mobilised into the circulation by @entity1261 help achieve rapid haematological reconstitution and are now the preferred source of stem cells over bone marrow for this form of therapy. @entity1261 is also used to support allogeneic transplantation, which exerts a therapeutic graft-versus- @entity706 effect. Administration of @entity1261 following autologous or allogeneic peripheral blood stem cell transplantation accelerates neutrophil recovery.
